whether angiotensin receptor blockers increase cancer or cardiovascular risk
August 2010
See updated FDA information regarding ARBs/cancer and Olmesartan/CV risks
ARBs and cancer. A recent analysis suggests that ARBs are associated with a small increased risk of cancer...about 1 more case for every 143 patients using an ARB instead of placebo for 4 years.
One theory is that angiotensin might be involved in cell growth. ARBs increase free angiotensin by blocking its receptors.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote